产品
编 号：F271923
分子式：C18H16F3IN2O2
分子量：476.23
分子式：C18H16F3IN2O2
分子量：476.23
产品类型
规格
价格
是否有货
结构图
CAS No: 212631-61-3
产品详情
生物活性：
PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects.
体内研究：
Intrathecal administration of PD 198306 (1-30 μg per 10 μL) dose-dependently (1-30 μg) blocks static allodynia in both the streptozocin and the chronic constriction injury (CCI) models of neuropathic pain.Animal Model:Male Sprague Dawley rats (250-300 g) bearing neuropathic pain
Dosage:1-30 μg per 10 μL and 3 mg per 100 μL (PD 198306 is suspended in cremophor:ethanol:water, 1 : 1 : 8.)
Administration:Single doses of intrathecal (i.t.) or intraplantar (ipl) of PD 198306 (1-30 μg per 10 μL and 3 mg per 100 μL respectively
Result:Intrathecal administration dose-dependently (1-30 μg) blocked static allodynia the streptozocin model of neuropathic pain. The minimum effective doses (MED) of 3 μg significantly blocked static allodynia 30 min after treatment. Both 10 μg and the highest dose used (30 μg) totally blocked the maintenance of static allodynia, for up to 1 h.
体外研究：
PD198306 significantly inhibits Tha-GFP replication by 25% at 10?μM, after 36?h.PD198306 (5?μM) reduces Tha-Crimson replication significantly by 20% at 18?h but such a result could not be confirmed at 36?h.
PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects.
体内研究：
Intrathecal administration of PD 198306 (1-30 μg per 10 μL) dose-dependently (1-30 μg) blocks static allodynia in both the streptozocin and the chronic constriction injury (CCI) models of neuropathic pain.Animal Model:Male Sprague Dawley rats (250-300 g) bearing neuropathic pain
Dosage:1-30 μg per 10 μL and 3 mg per 100 μL (PD 198306 is suspended in cremophor:ethanol:water, 1 : 1 : 8.)
Administration:Single doses of intrathecal (i.t.) or intraplantar (ipl) of PD 198306 (1-30 μg per 10 μL and 3 mg per 100 μL respectively
Result:Intrathecal administration dose-dependently (1-30 μg) blocked static allodynia the streptozocin model of neuropathic pain. The minimum effective doses (MED) of 3 μg significantly blocked static allodynia 30 min after treatment. Both 10 μg and the highest dose used (30 μg) totally blocked the maintenance of static allodynia, for up to 1 h.
体外研究：
PD198306 significantly inhibits Tha-GFP replication by 25% at 10?μM, after 36?h.PD198306 (5?μM) reduces Tha-Crimson replication significantly by 20% at 18?h but such a result could not be confirmed at 36?h.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备